Search research articles
Contact Us
Filters
Showing results (81-90 of 173) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2020
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
The Lancet. Oncology
|
October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
The Lancet. Oncology
|
December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 29, 2026
Quality and safety of research biopsies in oncology clinical trials
Paolo Nuciforo, Fiorella Ruiz-Pace, José Jimenez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2020
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux, Ana Oaknin, Swati Garg, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Dominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
Gynecologic Oncology
|
August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Nicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine
|
October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Dominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 173) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2020
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
The Lancet. Oncology
|
October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
The Lancet. Oncology
|
December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 29, 2026
Quality and safety of research biopsies in oncology clinical trials
Paolo Nuciforo, Fiorella Ruiz-Pace, José Jimenez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2020
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux, Ana Oaknin, Swati Garg, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Dominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
Gynecologic Oncology
|
August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Nicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine
|
October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Dominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
Page
of 18